Tanaka, M., Furuhashi, M., Moniwa, N., Maeda, T., Takizawa, H., Matsumoto, M., . . . Miura, T. (2020). Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria. BMC Nephrol.
Chicago-стиль цитированияTanaka, Marenao, et al. "Significance of Urinary Fatty Acid-binding Protein 4 Level As a Possible Biomarker for the Identification of Minimal Change Disease in Patents With Nephrotic-range Proteinuria." BMC Nephrol 2020.
MLA-цитированиеTanaka, Marenao, et al. "Significance of Urinary Fatty Acid-binding Protein 4 Level As a Possible Biomarker for the Identification of Minimal Change Disease in Patents With Nephrotic-range Proteinuria." BMC Nephrol 2020.